Roivant Sciences Ltd. (ROIV)
NASDAQ: ROIV · Real-Time Price · USD
11.04
+0.04 (0.36%)
Apr 25, 2025, 4:00 PM EDT - Market closed
Roivant Sciences Employees
Roivant Sciences had 908 employees as of March 31, 2024. The number of employees increased by 4 or 0.44% compared to the previous year.
Employees
908
Change (1Y)
4
Growth (1Y)
0.44%
Revenue / Employee
$135,006
Profits / Employee
-$128,437
Market Cap
7.86B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Mar 31, 2024 | 908 | 4 | 0.44% |
| Mar 31, 2023 | 904 | 41 | 4.75% |
| Mar 31, 2022 | 863 | 198 | 29.77% |
| Jun 30, 2021 | 665 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novartis AG | 75,883 |
ROIV News
- 2 days ago - Roivant Sciences: Primed For Growth With A De-Risked Pipeline - Seeking Alpha
- 5 days ago - Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402 - GlobeNewsWire
- 5 weeks ago - Roivant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies - GlobeNewsWire
- 5 weeks ago - Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs - GlobeNewsWire
- 7 weeks ago - Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna - GlobeNewsWire
- 2 months ago - Roivant Sciences Ltd. (ROIV) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Roivant Reports Financial Results for the Third Quarter Ended December 31, 2024, and Provides Business Update - GlobeNewsWire
- 2 months ago - Roivant: Telavant-Like Success Will Be Challenging To Replicate (Rating Downgrade) - Seeking Alpha